Company / Financials
Cardiff Oncology, Inc. Financials
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$593.0K
FY2025 · +21.5% YoY
Net Income
-$45.9M
FY2025 · -10.6% YoY
Profit Margin
-7732.0%
FY2025 · net income / revenue
ROE
-101.0%
FY2025 · return on equity
Total Assets
$61.9M
FY2025
Total Debt
-
FY2025
Equity
$45.4M
FY2025
ROA
-74.1%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$593.0K+21.5% YoYNet Income HistoryProfit after all expenses and taxes-$45.9M-10.6% YoYCost of Revenue HistoryDirect costs of producing goods and services sold-Operating Income HistoryProfit from core business operations before interest and taxes-$49.0M-7.8% YoYSG&A Expense HistorySelling, general, and administrative expenses$14.2M+9.1% YoYR&D Expense HistoryResearch and development spending$35.3M+7.5% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$0.95-2.2% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.95-2.2% YoY